Journal of Allergy and Clinical Immunology: Global (Aug 2024)

Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI)

  • Fernando Monteiro Aarestrup, MD, PhD,
  • Ernesto Akio Taketomi, MD, PhD,
  • Clóvis Eduardo Santos Galvão, MD, PhD,
  • Gil Bardini Alves, MD, MSc,
  • Geórgia Véras de Araújo Gueiros Lira, MD, PhD,
  • Marcos Reis Gonçalves, MD, MSc,
  • Mariana Graça Couto Miziara, MD,
  • Sidney Souteban Maranhão Casado, MD,
  • Veridiana Aun Rufino Pereira, MD, PhD,
  • Dirceu Solé, MD, PhD,
  • Ekaterini Simoes Goudouris, MD, PhD,
  • Fabio Chigres Kuschnir, MD, PhD

Journal volume & issue
Vol. 3, no. 3
p. 100281

Abstract

Read online

The use of allergen immunotherapy (AIT) in Brazil has specific regional conditions owing to the pattern of allergen sensitization, as well as to genetic, socioeconomic, and cultural characteristics. This review article aims to discuss the clinical practice of AIT by the subcutaneous or sublingual route in Brazil, addressing the possibilities of transition between these forms of administration. A systematic review using the PubMed and Cochrane databases was performed, and the websites of major allergy and immunology organizations were consulted. Knowledge of the mechanism of action of subcutaneous immunotherapy and sublingual immunotherapy, together with Brazilian real-life experience, allowed us to establish recommendations regarding switching routes of AIT administration in selected cases. Careful analysis of each clinical situation is necessary to perform the transition between subcutaneous and sublingual allergen immunotherapy.

Keywords